Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MB | P02144 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590962 | 0.90 | TYR (0.56) | POLBPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10888531 | 0.89 | TYR (0.55) | POLBPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2855498 | 0.88 | POLB (0.63) | POLBPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL13963716 | 0.83 | ALDH1A1 (0.51) | POLBSMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL8612459 | 0.80 | POLB (0.61) | POLBPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5837263 | 0.80 | POLB (0.54) | POLBPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29939067 | 0.79 | POLB (0.53) | POLBPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30780902 | 0.79 | POLB (0.53) | POLBPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9582949 | 0.79 | POLB (0.53) | POLBPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL28026046 | 0.78 | POLB (0.51) | POLBPKMSMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3223821-A1 | SUBSTITUTED PYRIDOBENZODIAZEPINONE-DERIVATIVES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-04 | — | — | EP | disclosed |
| US-20170253602-A1 | SUBSTITUTED PYRIDOBENZODIAZEPINONE-DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-07 | — | — | US | disclosed |
| WO-2016083276-A1 | SUBSTITUTED PYRIDOBENZODIAZEPINONE-DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-02 | — | — | WO | disclosed |
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | POLB 678/4885PKM 1419/4885SMN1; SMN2 1723/4885 |
| US-20170253602-A1 | SUBSTITUTED PYRIDOBENZODIAZEPINONE-DERIVATIVES AND USE THEREOF | BDKRB2, BDKRB1, PDGFRB | POLB 1103/4885PKM 577/4885SMN1; SMN2 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.